<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Galapagos Nv — News on 6ix</title>
<link>https://6ix.com/company/galapagos-nv-1</link>
<description>Latest news and press releases for Galapagos Nv on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 20:01:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/galapagos-nv-1" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d54942beedb30cb6f75f7a.webp</url>
<title>Galapagos Nv</title>
<link>https://6ix.com/company/galapagos-nv-1</link>
</image>
<item>
<title>Galapagos’ Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders’ Meetings 2026</title>
<link>https://6ix.com/company/galapagos-nv-1/news/galapagos-shareholders-adopt-all-resolutions-proposed-by-the-board-of-directors-at-the-annual-and-extraordinary-shareholders-meetings-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/galapagos-nv-1/news/galapagos-shareholders-adopt-all-resolutions-proposed-by-the-board-of-directors-at-the-annual-and-extraordinary-shareholders-meetings-2026-1</guid>
<pubDate>Tue, 28 Apr 2026 20:01:00 GMT</pubDate>
<description>Mechelen, Belgium; April 28, 2026, 22:01 CET — Galapagos NV (Euronext & NASDAQ: GLPG) today announces that all resolutions proposed at the Company’s Annual and Extraordinary Shareholders’ Meetings (AGM and EGM) held on 28 April 2026 were approved. The AGM approved, amongst other items: The Annual Report and the Remuneration ReportThe remuneration of the members of the Board of DirectorsThe appointment of Mr. Henry Gosebruch as Executive DirectorThe appointments of Dr. Jane Griffiths, Ms. Dawn Sv</description>
</item>
<item>
<title>Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases</title>
<link>https://6ix.com/company/galapagos-nv-1/news/galapagos-and-gilead-enter-into-binding-agreement-to-collaborate-on-advancing-first-in-class-t-cell-engager-program-for-autoimmune-diseases-2</link>
<guid isPermaLink="true">https://6ix.com/company/galapagos-nv-1/news/galapagos-and-gilead-enter-into-binding-agreement-to-collaborate-on-advancing-first-in-class-t-cell-engager-program-for-autoimmune-diseases-2</guid>
<pubDate>Tue, 31 Mar 2026 05:30:00 GMT</pubDate>
<description>New collaboration structure achieves meaningfully improved financial terms and flexibility for Galapagos Following this transaction, the Company will continue to have a majority of its cash remaining for additional strategic transactions and other capital allocation priorities Opportunity to develop a potential first-in-class & best-in-class T cell engager in autoimmune diseases with gamgertamig Management to host conference call today, March 31, 2026, at 14:00 CET / 8:00 am ET Mechelen, Belgium</description>
</item>
<item>
<title>Galapagos Announces Nomination of Gino Santini to its Board of Directors</title>
<link>https://6ix.com/company/galapagos-nv-1/news/galapagos-announces-nomination-of-gino-santini-to-its-board-of-directors-1</link>
<guid isPermaLink="true">https://6ix.com/company/galapagos-nv-1/news/galapagos-announces-nomination-of-gino-santini-to-its-board-of-directors-1</guid>
<pubDate>Thu, 26 Mar 2026 20:02:00 GMT</pubDate>
<description>Subject to his election by shareholders, the Board intends to appoint Mr. Santini as Chair, succeeding Jérôme Contamine Mr. Santini will bring extensive corporate governance, business development and industry leadership experience to the Board Mechelen, Belgium; March 26, 2026, 21:02 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced the proposed appointment of Gino Santini as a Non-Executive Independent Director, with the intention to appoint him as Chair of its Board of Directors, s</description>
</item>
<item>
<title>Galapagos Publishes 2025 Annual Report and Announces Annual and Extraordinary Shareholders’ Meetings</title>
<link>https://6ix.com/company/galapagos-nv-1/news/galapagos-publishes-2025-annual-report-and-announces-annual-and-extraordinary-shareholders-meetings-1</link>
<guid isPermaLink="true">https://6ix.com/company/galapagos-nv-1/news/galapagos-publishes-2025-annual-report-and-announces-annual-and-extraordinary-shareholders-meetings-1</guid>
<pubDate>Thu, 26 Mar 2026 20:01:00 GMT</pubDate>
<description>Mechelen, Belgium; March 26, 2026, 21:01 CET; regulated information — Galapagos NV (Euronext & NASDAQ: GLPG) today published its annual report for the financial year 2025 and announced that its Annual Shareholders’ Meeting (AGM) and an Extraordinary Shareholders' Meeting (EGM) will be held sequentially on Tuesday, April 28, 2026 at 14:00 CET and 15:00 CET at Schaliënhoevedreef 20T, 2800 Mechelen, Belgium. The annual report for the financial year 2025, including a review of figures and performanc</description>
</item>
<item>
<title>Galapagos and Gilead in Advanced Discussions to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases</title>
<link>https://6ix.com/company/galapagos-nv-1/news/galapagos-and-gilead-in-advanced-discussions-to-collaborate-on-advancing-first-in-class-t-cell-engager-program-for-autoimmune-diseases-1</link>
<guid isPermaLink="true">https://6ix.com/company/galapagos-nv-1/news/galapagos-and-gilead-in-advanced-discussions-to-collaborate-on-advancing-first-in-class-t-cell-engager-program-for-autoimmune-diseases-1</guid>
<pubDate>Mon, 23 Mar 2026 22:25:00 GMT</pubDate>
<description>Galapagos intends to enter into a strategic collaboration with Gilead following Gilead's acquisition of Ouro Medicines New partnership structure would achieve meaningfully improved financial terms and flexibility for Galapagos Following this potential transaction, the Company will continue to have a majority of its capital available for additional strategic transactions and other capital allocation priorities Mechelen, Belgium; March 23, 2026, 23:02 CET; regulated information – inside informatio</description>
</item>
<item>
<title>Galapagos Receives Transparency Notification from Bank of America</title>
<link>https://6ix.com/company/galapagos-nv-1/news/galapagos-receives-transparency-notification-from-bank-of-america</link>
<guid isPermaLink="true">https://6ix.com/company/galapagos-nv-1/news/galapagos-receives-transparency-notification-from-bank-of-america</guid>
<pubDate>Tue, 17 Mar 2026 21:01:00 GMT</pubDate>
<description>Mechelen, Belgium; March 117, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Bank of America. Pursuant to Belgian transparency legislation1, Galapagos received transparency notification from Bank of America Corporation on March 12, 2026. The notification indicates that Bank of America Corporation, as controlling entity, fell below the 5% threshold for of Galapagos’ voting rights on March 10, 2026, as a result of the dispo</description>
</item>
<item>
<title>Galapagos Receives Transparency Notifications from Bank of America</title>
<link>https://6ix.com/company/galapagos-nv-1/news/galapagos-receives-transparency-notifications-from-bank-of-america-57</link>
<guid isPermaLink="true">https://6ix.com/company/galapagos-nv-1/news/galapagos-receives-transparency-notifications-from-bank-of-america-57</guid>
<pubDate>Tue, 10 Mar 2026 21:01:00 GMT</pubDate>
<description>Mechelen, Belgium; March 10, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received transparency notifications from Bank of America. Pursuant to Belgian transparency legislation1, Galapagos received transparency notifications from Bank of America Corporation on March 5 and 6, 2026. The initial notification indicates that Bank of America Corporation, as controlling entity, fell below the 5% threshold for equivalent financial instruments relating to Galapagos’ vot</description>
</item>
<item>
<title>Galapagos Creates New Subscription Right Plan</title>
<link>https://6ix.com/company/galapagos-nv-1/news/galapagos-creates-new-subscription-right-plan-1</link>
<guid isPermaLink="true">https://6ix.com/company/galapagos-nv-1/news/galapagos-creates-new-subscription-right-plan-1</guid>
<pubDate>Fri, 06 Mar 2026 21:01:00 GMT</pubDate>
<description>Mechelen, Belgium; March 6, 2026, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,750,000 subscription rights under a new subscription right plan. On March 6, 2026, the Board of Directors of Galapagos approved the “Subscription Right Plan 2026”, intended for personnel of the Company and its subsidiaries, within the framework of the authorized capital. Under this subscription right plan, 1,750,000 subscription rights</description>
</item>
<item>
<title>Galapagos Appoints Tania Philipp as Chief Human Resources Officer</title>
<link>https://6ix.com/company/galapagos-nv-1/news/galapagos-appoints-tania-philipp-as-chief-human-resources-officer-32</link>
<guid isPermaLink="true">https://6ix.com/company/galapagos-nv-1/news/galapagos-appoints-tania-philipp-as-chief-human-resources-officer-32</guid>
<pubDate>Thu, 05 Mar 2026 21:01:00 GMT</pubDate>
<description>Seasoned Life Sciences Executive Joins Galapagos with Strong Track Record in Change Management Mechelen, Belgium; March 5, 2026, 22:01 CET — Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointment of Tania Philipp as Chief Human Resources Officer (CHRO), effective March 4, 2026. Ms. Philipp will also join the Management Committee. She succeeds Annelies Missotten, who will remain with the company through June 30, 2026, to ensure a smooth transition. Ms. Philipp brings nearly three</description>
</item>
<item>
<title>Galapagos Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update</title>
<link>https://6ix.com/company/galapagos-nv-1/news/galapagos-reports-full-year-2025-financial-results-and-provides-fourth-quarter-business-update-1</link>
<guid isPermaLink="true">https://6ix.com/company/galapagos-nv-1/news/galapagos-reports-full-year-2025-financial-results-and-provides-fourth-quarter-business-update-1</guid>
<pubDate>Mon, 23 Feb 2026 21:01:00 GMT</pubDate>
<description>Strategic reset positions Galapagos for long-term value creation Robust 2025 year-end cash and financial investments of €3.0 billion and ongoing collaboration with Gilead enable flexibility to execute on a business development-led growth strategy 2026 year-end cash expected to be in the range of €2.775 to €2.850 billion, with reduced cell therapy one-time restructuring cash costs of €25 million to an updated range of €125 to €175 million Management to host conference call tomorrow, February 24,</description>
</item>
<item>
<title>Galapagos Welcomes Dr. Paulo Fontoura to its Board of Directors</title>
<link>https://6ix.com/company/galapagos-nv-1/news/galapagos-welcomes-dr-paulo-fontoura-to-its-board-of-directors-2</link>
<guid isPermaLink="true">https://6ix.com/company/galapagos-nv-1/news/galapagos-welcomes-dr-paulo-fontoura-to-its-board-of-directors-2</guid>
<pubDate>Thu, 19 Feb 2026 21:01:00 GMT</pubDate>
<description>Dr. Fontoura brings extensive global leadership, clinical development, and operational experience to the Board Mechelen, Belgium; February 19, 2026, 22:01 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced the appointment by way of co-optation of Dr. Paulo Fontoura as Non-Executive Independent Director to its Board of Directors, effective February 9, 2026. “We are pleased to welcome Paulo to our Board,” said Jérôme Contamine, Chair of the Board of Galapagos. “His global leadership exp</description>
</item>
<item>
<title>Third Arc Bio Announces $52M Series A Extension to Expand Oncology and Immunology & Inflammation Portfolio</title>
<link>https://6ix.com/company/galapagos-nv-1/news/third-arc-bio-announces-dollar52m-series-a-extension-to-expand-oncology-and-immunology-and-inflammation-portfolio-1</link>
<guid isPermaLink="true">https://6ix.com/company/galapagos-nv-1/news/third-arc-bio-announces-dollar52m-series-a-extension-to-expand-oncology-and-immunology-and-inflammation-portfolio-1</guid>
<pubDate>Wed, 04 Feb 2026 12:00:00 GMT</pubDate>
<description>Third Arc Bio Inc., a clinical stage biotech company developing novel multifunctional antibodies for a range of oncology and immunology & inflammation (I&I) indications, today announced the closing of a $52 million Series A extension.</description>
</item>
<item>
<title>Galapagos Announces Board Decision to Initiate Wind-Down of Cell Therapy Activities</title>
<link>https://6ix.com/company/galapagos-nv-1/news/galapagos-announces-board-decision-to-initiate-wind-down-of-cell-therapy-activities</link>
<guid isPermaLink="true">https://6ix.com/company/galapagos-nv-1/news/galapagos-announces-board-decision-to-initiate-wind-down-of-cell-therapy-activities</guid>
<pubDate>Mon, 05 Jan 2026 21:01:00 GMT</pubDate>
<description>Mechelen, Belgium; January 5, 2026, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the works council consultation process regarding the wind-down of cell therapy activities has been completed and its Board of Directors has decided to initiate the wind-down of the Company’s cell therapy activities. On October 21, 2025, Galapagos announced its intention to wind down its cell therapy activities following a comprehensive strategic review and sale process, including an explora</description>
</item>
<item>
<title>Galapagos Announces Topline Results from Two Phase 3-Enabling Studies with Selective TYK2 Inhibitor GLPG3667 in Dermatomyositis and Systemic Lupus Erythematosus</title>
<link>https://6ix.com/company/galapagos-nv-1/news/galapagos-announces-topline-results-from-two-phase-3-enabling-studies-with-selective-tyk2-inhibitor-glpg3667-in-dermatomyositis-and-systemic-lupus-erythematosus</link>
<guid isPermaLink="true">https://6ix.com/company/galapagos-nv-1/news/galapagos-announces-topline-results-from-two-phase-3-enabling-studies-with-selective-tyk2-inhibitor-glpg3667-in-dermatomyositis-and-systemic-lupus-erythematosus</guid>
<pubDate>Thu, 18 Dec 2025 21:01:00 GMT</pubDate>
<description>GLPG3667 met primary endpoint in dermatomyositis study, demonstrating a statistically significant clinical benefit and meaningful improvements on secondary measures of disease activity compared to placebo In the systemic lupus erythematosus study, GLPG3667 delivered numerical improvements on several secondary endpoints compared to placebo but did not achieve statistical significance in primary endpoint analysis The safety profile was consistent with previous studies with GLPG3667 Galapagos will</description>
</item>
<item>
<title>Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025</title>
<link>https://6ix.com/company/galapagos-nv-1/news/galapagos-presented-new-atalanta-1-cell-therapy-data-in-mcl-at-ash-2025</link>
<guid isPermaLink="true">https://6ix.com/company/galapagos-nv-1/news/galapagos-presented-new-atalanta-1-cell-therapy-data-in-mcl-at-ash-2025</guid>
<pubDate>Mon, 08 Dec 2025 06:30:00 GMT</pubDate>
<description>High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time Mechelen, Belgium; December 8, 2025, 07:30 CET; Galapagos NV (Euronext & NASDAQ: GLPG) announced new and updated Phase 2 data from the ongoing ATALANTA-1 study with its CD19 CAR T-cell therapy candidate, GLPG5101, during an oral presentation (#662) at the 67th Ame</description>
</item>
<item>
<title>Galapagos Reports Nine Months 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/galapagos-nv-1/news/galapagos-reports-nine-months-2025-financial-results-and-provides-business-update-1</link>
<guid isPermaLink="true">https://6ix.com/company/galapagos-nv-1/news/galapagos-reports-nine-months-2025-financial-results-and-provides-business-update-1</guid>
<pubDate>Wed, 05 Nov 2025 21:01:00 GMT</pubDate>
<description>Strategic review process concluded with intention to wind down cell therapy business, representing optimal capital allocation pathway to support a stronger and sustainable future for GalapagosContinued evolution of leadership team aligned with strategic directionRobust balance sheet with €3.05 billion in cash and financial investments as of September 30, 2025; year-end 2025 cash position expected at €2.975 billion to €3.025 billion Management to host a conference call tomorrow, November 6, 2025,</description>
</item>
<item>
<title>Galapagos to Present New Data from Cell Therapy Program at ASH 2025</title>
<link>https://6ix.com/company/galapagos-nv-1/news/galapagos-to-present-new-data-from-cell-therapy-program-at-ash-2025</link>
<guid isPermaLink="true">https://6ix.com/company/galapagos-nv-1/news/galapagos-to-present-new-data-from-cell-therapy-program-at-ash-2025</guid>
<pubDate>Mon, 03 Nov 2025 21:01:00 GMT</pubDate>
<description>Oral presentation of GLPG5101 data from the ATALANTA-1 study in patients with high-risk relapsed/refractory mantle cell lymphoma Two abstracts featuring new Phase 2 data highlight the potential of CAR-T cell therapy candidate, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma Results demonstrate high rates of complete and durable responses along with low rates of high-grade toxicities using GLPG5101 manufactured on innovative median seven-day vein-to-vein time platform, potentially enabling</description>
</item>
<item>
<title>Galapagos Announces Changes to its Board to Accelerate Strategic Focus on Business Development</title>
<link>https://6ix.com/company/galapagos-nv-1/news/galapagos-announces-changes-to-its-board-to-accelerate-strategic-focus-on-business-development</link>
<guid isPermaLink="true">https://6ix.com/company/galapagos-nv-1/news/galapagos-announces-changes-to-its-board-to-accelerate-strategic-focus-on-business-development</guid>
<pubDate>Thu, 30 Oct 2025 20:01:00 GMT</pubDate>
<description>New Directors bring strong financial leadership, capital allocation, and business development expertise to the Board Mechelen, Belgium; October 30, 2025, 21:01 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced several changes to its Board of Directors as part of its ongoing commitment to long-term governance and strategic continuity. These changes strengthen the alignment of the Board’s composition with the Company’s strategic direction and support its focus on transformational busin</description>
</item>
<item>
<title>Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors</title>
<link>https://6ix.com/company/galapagos-nv-1/news/galapagos-to-present-in-vitro-data-at-acr-convergence-2025-suggesting-differentiation-of-glpg3667-from-other-tyk2-inhibitors</link>
<guid isPermaLink="true">https://6ix.com/company/galapagos-nv-1/news/galapagos-to-present-in-vitro-data-at-acr-convergence-2025-suggesting-differentiation-of-glpg3667-from-other-tyk2-inhibitors</guid>
<pubDate>Thu, 23 Oct 2025 20:01:00 GMT</pubDate>
<description>Mechelen, Belgium; October 23, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present new in vitro pharmacological data from its selective TYK2 inhibitor, GLPG3667, currently in two Phase 3-enabling studies in dermatomyositis (DM) and systemic lupus erythematosus (SLE), at the American College of Rheumatology (ACR) Convergence 2025, taking place in Chicago, IL, October 24-29, 2025. The data show that the in vitro pharmacological profile of GLPG3667 suggests</description>
</item>
<item>
<title>Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company’s Ongoing Transformation</title>
<link>https://6ix.com/company/galapagos-nv-1/news/galapagos-announces-intention-to-wind-down-cell-therapy-business-as-part-of-the-companys-ongoing-transformation</link>
<guid isPermaLink="true">https://6ix.com/company/galapagos-nv-1/news/galapagos-announces-intention-to-wind-down-cell-therapy-business-as-part-of-the-companys-ongoing-transformation</guid>
<pubDate>Tue, 21 Oct 2025 05:30:00 GMT</pubDate>
<description>Intention follows comprehensive strategic review process and would represent the optimal capital allocation pathway to support a stronger and sustainable future for Galapagos Mechelen, Belgium; October 21, 2025, 07:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced its intention to wind down its cell therapy business and pursue new transformational business development transactions with its available cash resources. The intention to wind d</description>
</item>
</channel>
</rss>